Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held by Leap Therapeutics, Inc. on July 2, 2024. The filing details the voting outcomes for director elections, executive compensation, equity plan amendments, and auditor ratification. Note: The request metadata lists "CYPHERPUNK TECHNOLOGIES INC.", but the filing text explicitly identifies the registrant as Leap Therapeutics, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections (Class I): All four nominees were elected to serve until the 2027 annual meeting.
- James Cavanaugh: 16,740,789 votes for; 1,392,072 withheld.
- Douglas E. Onsi: 17,084,768 votes for; 1,048,093 withheld.
- Christian Richard: 17,809,064 votes for; 323,797 withheld.
- Richard Schilsky: 16,813,357 votes for; 1,319,504 withheld.
- Executive Compensation (Say-on-Pay): Approved on an advisory basis with 16,820,682 votes for and 1,272,059 votes against.
- Equity Incentive Plan Amendment: The amendment to the 2022 Equity Incentive Plan was approved with 16,572,103 votes for and 1,480,150 votes against.
- Auditor Ratification: EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 25,894,496 votes for and 71,613 votes against.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It is strictly a disclosure of voting results.
Investor Verification Checklist
- Verify the company name discrepancy between the request metadata (Cypherpunk Technologies Inc.) and the filing (Leap Therapeutics, Inc.).
- Confirm the tenure of the newly elected Class I directors (through 2027).
- Review the specific terms of the approved amendment to the 2022 Equity Incentive Plan in the company's proxy statement.
- Check the upcoming fiscal year-end (December 31, 2024) for the newly ratified auditor, EisnerAmper LLP.